News brief­ing: Fre­quen­cy posts ex­tend­ed pos­i­tive re­sults for hear­ing loss pro­gram; Kiniksa earns ODD for GCA can­di­date

Fre­quen­cy Ther­a­peu­tics pre­sent­ed re­sults from a longer-term dura­bil­i­ty study of its ac­quired sen­sorineur­al hear­ing loss can­di­date, say­ing FX-322 showed sig­nif­i­cant im­prove­ment for some pa­tients in key mea­sures of hear­ing that were sus­tained for up to 21 months.

The da­ta build up­on Phase I/II re­sults from 2019 where the pro­gram demon­strat­ed sta­tis­ti­cal­ly sig­nif­i­cant im­prove­ments in word recog­ni­tion scores in pa­tients with chron­ic SNHL, Fre­quen­cy said. That study last­ed for on­ly 90 days, where­as Tues­day’s new da­ta were part of sub­se­quent test­ing of a sub­set of these pa­tients be­tween 13 and 21 months af­ter ini­tial dos­ing.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.